

Preliminary Program

Annual Congress SGAI-SSAI Spring Meeting SGDV-SSDV



April 19–20, 2007
Congress Center Basel

www.ctlag-congress.ch

 SOCIÉTÉ SUISSE D'ALLERGOLOGIE ET D'IMMUNOLOGIE
SCHWEIZ. GESELLSCHAFT FÜR ALLERGOLOGIE UND IMMUNOLOGIE
SWISS SOCIETY FOR ALLERGOLOGY AND IMMUNOLOGY
www.ssai-sgai.ch

 Schweizerische
Gesellschaft
Dermatologie
Venerologie
www.derma.ch



Today,
allergies
don't
just grow on
trees



Xyzal® receptor occupancy
predicts a potent
antihistamine¹



We all know about allergies, like the hayfever you get in the park or countryside. But these days, more and more of us live in cities and towns and yet allergies haven't gone away. In fact, they're worse because, quite apart from the stress it causes, modern living has brought with it a range of new allergens in our environment and in our homes. Today, staying out of the park or countryside does not guarantee that you can avoid allergies. Xyzal® is a potent solution to today's problem, an antihistamine with the persistence to control the symptoms of your allergy, no matter what modern life throws at you.^{2,3,4}



W: Levocetirizindihydrochlorid. **I:** Erwachsene und Kinder ab 6 Jahren: Allergische Rhinitis, saisonal und perennal (Heuschnupfen, Pollinosis) und persistierend, allergische Konjunktivitis und chronische idiopathische Urtikaria; Kinder von 2 bis 6 Jahren: saisonale Rhinitis. **D:** empfohlene Tagesdosierung Erwachsene und Kinder ab 6 Jahren: 5 mg (1 Filmtablette oder 20 Tropfen); Erwachsene: 1 x pro Tag; Kinder 6–12 Jahre: Dosis auf zwei Einnahmen verteilt; Kinder 2–6 Jahre: empfohlene Tagesdosierung 2,5 mg (5 Tropfen 2 x pro Tag). **E:** Einnahme kann zu oder unabhängig von Mahlzeiten erfolgen. **K:** Überempfindlichkeit auf Inhaltsstoffe, Piperazinderivate; Patienten mit terminaler Niereninsuffizienz (Clearance <10 ml/min). **UW:** Somnolenz, Mundtrockenheit, Kopfschmerzen, Müdigkeit, Asthenie. **I:** keine klinisch relevanten Wechselwirkungen mit anderen Medikamenten erwartet. **Packungen:** 10, 30 und 50 Filmtabletten, Tropfen 20 ml. **Liste B, Kassenzulässig.** Ausführliche Information siehe Arzneimittel-Kompendium der Schweiz. Ein Original-Präparat von UCB-Pharma AG, 1630 Bulle. **Referenzen:** 1. Gillard M et al. *Inflamm Res.* et al. 2005 Sep; 54(9):367-9. 2. Day JH et al. *J Clin Pract* 2004; 58: 109-18. 3. Purohit A et al. *BR J Clin Pharmacol.* 2003; 56(4): 388-94. 4. Bachert C et al. *J Allergy Clin Immunol.* 2004; 114: 838-844.

Welcome to Basel

Dear colleagues

It is a great pleasure to invite you to the combined annual congress of the Swiss Society of Allergy and Immunology and the spring meeting of the Swiss Society of Dermatology and Venerology which will be held at the Congress Center Basel on April 19–20, 2007.

The program will focus on recent advances in research as well as clinical care in basic and clinical immunology, allergology and dermatology. The topics presented include stem cells, development of the immune system, autoimmunity, tolerance induction, programmed cell death, innate immunity, modifiers of biological responses, targeted cell therapy, inflammatory skin disorders and others. In three parallel symposia in basic immunology, clinical immunology and allergy and dermatology and in clinical case seminars we hope to fulfil the scientific demand of the broadly interested as well as of the specialist. State-of-the-art lectures will provide an overview of hot scientific topics and try to amalgamate basic with clinical interests.

An important goal of this congress is to give to our younger colleagues a scientific meeting platform and we encourage them to submit abstracts for the poster and oral sessions. As usual, the best posters will be awarded with prizes.

It is also a great privilege to welcome our renowned speakers who will share with us their data and views, and the chairmen who will moderate the sessions.

Finally, we very much appreciate the participation of numerous companies in the industry exhibition, and are grateful to them and all sponsors for their support.

On behalf of the organizing committee



Peter Erb

President of the organizing committee

Program Overview

Thursday, April 19, 2007

08.30–10.00	Registration
09.30–10.00	Welcome Coffee, Poster Exhibition, Industry Exhibition
10.00–10.15	Welcome and Introduction
10.15–11.00	MAIN SYMPOSIUM I E. Sprecher, IL: Genes – Skin – Immunity
11.00–11.30	Coffee Break Poster Exhibition, Industry Exhibition
11.30–12.30	PARALLEL SYMPOSIUM A1: Basic Immunology D. Kioussis, UK: Imaging the development of the lymphoid system M.G. Manz, CH: Regulation of dendritic cell development
11.30–12.30	PARALLEL SYMPOSIUM A2: Clinical Immunology D. Jayne, UK: Vasculitis: Classification and pathophysiology update H.U. Simon, CH: Eosinophilia and vasculitis
11.30–12.30	PARALLEL SYMPOSIUM A3: Allergy/Dermatology J.H. Saurat, CH: Atopic Dermatitis – a unifying concept B. Nickoloff, USA: Psoriasis – an autoimmune disorder?
12.30–14.00	Lunch Break, Poster Exhibition, Industry Exhibition
12.45–13.45	PRACTITIONERS FORUM
12.45–13.45	SATELLITE SYMPOSIUM: Topical treatment of allergic rhinitis – how can we do better? (Glaxo SmithKline AG)
14.00–15.30	PARALLEL SYMPOSIUM B1: Basic Immunology M. Hengartner, CH: Programmed cell death: What have we learned from <i>C. elegans</i> ? A. Strasser, AUS: Molecular control of apoptosis in the immune system M.J. Lenardo, USA: Molecular regulation of cell death and lymphocyte function
14.00–15.30	PARALLEL SYMPOSIUM B2: Clinical Immunology A. Tyndall, CH: Adult stem cell therapy of autoimmune disease P. Muraro, UK: Immune reconstitution – resetting the immune system P.A. Knolle, D: Endothelial cell function and dysfunction in autoimmunity
14.00–15.30	PARALLEL SYMPOSIUM B3: Allergy/Dermatology R. Happle, D: Hereditary immunodeficiency and revertant mosaicism: The paradigm of natural gene therapy P. Itin, CH: DNA repair disorders and immunodeficiency M. Pirmohamed, UK: Pharmacogenetics/Metabolic activation in drug hypersensitivity
15.30–16.00	Coffee Break, Poster Exhibition, Industry Exhibition
16.00–17.00	FREE COMMUNICATIONS: Basic Immunology
16.00–17.00	FREE COMMUNICATIONS: Clinical Immunology
16.00–17.00	FREE COMMUNICATIONS: Allergy/Dermatology
17.00–17.15	Break
17.15–18.30	General Assembly SGAI/SSAI
19.30–23.30	Gala Dinner at the Hotel «Les Trois Rois», Basel

Program Overview

Friday, April 20, 2007

07.30–08.30	Registration
08.30–10.00	MAIN SYMPOSIUM II H. Waldmann, UK: Prospects for harnessing tolerance in therapy R. Ricci, CH: Atherosclerosis – an immune disease
10.00–10.30	Coffee Break, Poster Exhibition, Industry Exhibition
10.30–12.00	PARALLEL SYMPOSIUM C1: Basic Immunology B. Rocha, F: Effector genes expression and association in immune responses D. Nemazee, USA: Antibody responses without TLR signaling B. Stockinger, UK: Tolerance induction in the periphery
10.30–12.00	PARALLEL SYMPOSIUM C2: Clinical Immunology M. Feldmann, UK: Anti-TNF: The beginning of anti-cytokine medicine K. Smith, UK: Transcriptome analysis and the assessment of new therapies for autoimmune disease H. H. Peter, D: Rheumatic disease treatment with modifiers of the biological response
10.30–12.00	PARALLEL SYMPOSIUM C3: Allergy/Dermatology A. Gratwohl, CH: Graft-versus-Host Disease: An allo- or autoimmune disease? D. Lipsker, F: Dermatologic clues to diagnosis of systemic rheumatologic diseases L. Borradori, CH: Autoimmune bullous disorders
12.00–13.30	Lunch Break, Poster Exhibition, Industry Exhibition
12.15–13.15	SATELLITE SYMPOSIUM: The practical use of Efalizumab (Sereno Pharma Schweiz)
13.30–14.30	PARALLEL SYMPOSIUM D1: Basic Immunology H. G. Rammensee, D: Titel to be announced H. Wagner, D: The immunobiology of nucleotide-recognizing Toll-like receptors 7–9 (TLRs 7–9)
13.30–14.30	PARALLEL SYMPOSIUM D2: Clinical Immunology C. Rooney, USA: Virus-specific cell therapy P. Comoli, I: Fungus-specific cell therapy
13.30–14.30	PARALLEL SYMPOSIUM D3: Allergy/Dermatology Audience interactive clinical case seminar
14.30–15.30	FREE COMMUNICATIONS: Basic Immunology
14.30–15.30	FREE COMMUNICATIONS: Clinical Immunology
14.30–15.30	FREE COMMUNICATIONS: Allergy/Dermatology
15.30–16.00	Coffee Break, Poster Exhibition, Industry Exhibition
16.00–16.45	MAIN SYMPOSIUM III P. Friedl, D: Amoeboid cell migration: Key determinant in immune cell communication and cancer cell dissemination
16.45–17.15	Poster prizes / Closing remarks

Gegen Akne

Das Spirig Dermatologie Programm.



Attraktiv in Preis und Service.

Tretinac® Minac® 50 Feminac 35® Aknefug® BP5 Aknecolor® Procutol®

Tretinac®: Z: Isotretinoin - Kapseln: 10 mg, 20 mg. **I:** Schwere Akne. **D:** Zum Essen, in 1-2 Gaben; initial 0,5 mg/kg tgl., dann individuell anpassen bis max. 2,0 mg/kg tgl. **K:** Leber- und Nierensuffizienz, gleichzeitige Anwendung mit Tetracyclinen, SS/SZ. **Liste:** A, SL. **Minac® 50:** Z: Minocyclin, Kapseln: 50 mg. **I:** Akne. **D:** 1 Kps. morgens und abends mit dem Essen, mind. 4-6 Wo. **K:** Überempfindlichkeit, schwere Nieren- und Leberfunktionsstörungen, SS/SZ. **Liste:** A, SL. **Feminac® 35:** Z: Dragees: 2 mg Cyproteronacetat, 35 µg Ethinylestradiol. **I:** Kontrazeption bei Frauen mit Androgenisierungsscheinungen. **D:** 1 Drag. tgl. vom 1.-21. Zyklustag, dann 7 Tage Pause. **K:** Leberfunktionsstör., thromboembolische Prozesse, SS/SZ. **Liste:** B. **Aknefug® BP 5:** Z: Benzoylperoxid, Emulsion: 50 mg/ml. **I:** Acne vulgaris. **D:** 1-2x tgl. **K:** Augen-, Schleimhautkontakt. **Liste:** C, SL. **Aknecolor®:** Z: Clotrimazol, Crempaste: 10 mg/g. **I:** Akne vulgaris. **D:** 1-2x tgl. **K:** Augen-, Schleimhautkontakt. **Liste:** C. **Procutol®:** Z: Triclosan, Lotion: 10 mg/ml. **I:** Antiseptische Hautreinigung. **D:** Wie Seife verwenden. **Liste:** D, SL. Ausführliche Angaben siehe Arzneimittelkompendium der Schweiz.

General Information

Date

April 19–20, 2007

Congress Venue

Congress Center Basel
Messeplatz 21, CH-4058 Basel
Tel. +41 58 206 27 09, Fax +41 58 206 21 86

Homepage

www.ctlag-congress.ch

Members of the Organizing Committee

Peter Erb, Basel (Congress President)
Andreas Bircher, Basel
Gennaro De Libero, Basel
Daniela Finke, Basel

Peter Itin, Basel
Martin Pletscher, Basel
Alan Tyndall, Basel

Members of the Scientific Committee

Barbara Biedermann, Basel
Reinhard Dummer, Zurich
Urs Eriksson, Basel
Ursula Günthert, Basel
Christoph Heusser, Basel
Hans Hirsch, Basel
Georg Holländer, Basel

Regine Landmann, Basel
Ed Palmer, Basel
Gerd Pluschke, Basel
Jan Pieters, Basel
Antonius Rolink, Basel
Jürg Schifferli, Basel
Giulio Spagnoli, Basel

Administrative Congress Organization

Convention Team Lucerne AG
Oberseeburg 10, CH-6006 Lucerne
Tel. +41 41 371 18 60, Fax +41 41 371 18 61
E-mail: info@ctlag-congress.ch

Important Deadlines

Abstracts: December 15, 2006, at the latest
Hotel reservation: February 10, 2007
Early registration: until March 1, 2007

Congress Language

English (no simultaneous translation)

General Information

Credits

Swiss Society of Dermatology and Venerology	8 credits per day
Swiss Society of Pediatrics	10 credits
Swiss Society of Otorhinolaryngology	8 credits
Swiss Society for Allergology and Immunology	16 credits
Swiss Society of Rheumatology	12 credits
Swiss Society of Internal Medicine	10.5 credits
Swiss Society of General Medicine	15 credits
Swiss Society of Medical Oncology	2 credits, cat B
Swiss Society for Infectious Diseases	9 credits
Swiss Federal Veterinary Office	Recommendation 2 days «Tierversuchsbewilligung» under evaluation

Registration Fees

	1 day Before 1.3.2007	1 day After 1.3.2007	2 days Before 1.3.2007	2 days After 1.3.2007
SSAI Members	CHF 150.–	CHF 200.–	CHF 200.–	CHF 250.–
SSDV Members	Registration fee is included in the annual membership fee			
Non-members	CHF 170.–	CHF 220.–	CHF 220.–	CHF 270.–
Assistant doctors/ PhD students	CHF 50.–	CHF 100.–	CHF 100.–	CHF 150.–
Gala Dinner	CHF 120.–	CHF 120.–		

Method of payment

Payment should be made by

Banktransfer to (free of charge)

Bank: UBS AG, CH-6002 Lucerne (BC 248)

Beneficiary: Convention Team Lucerne AG

Account: 469471.13F

Remark: «SSAI/SSDV2007»

IBAN: CH880024824846947113F

BIC: UBSWCHZH80A

Credit cards (VISA, MasterCard)

General Information

Registration

Please use the enclosed registration form and return it before March 1, 2007. After receipt of the registration fee, you will receive a written confirmation.

(Download form from www.ctlag-congress.ch for payment by credit card/Online registration possible for payment by bank transfer)

Abstracts

Abstracts for oral or poster presentations can be submitted on our website (www.ctlag-congress.ch). The abstracts will be published in the journal «Swiss Medical Weekly». The decision of the Scientific Committee as well as further information will be communicated to the authors by the end of January 2007.

Deadline for submission: December 15, 2006

Cancellation

Cancellations until March 1, 2007: Refund of total amount paid minus CHF 50.– per person for administrative charges. No refund after this date. Cancellations must be written to the congress organization.

Hotel Accommodation

Please use the hotel reservation form for accommodation as early as possible.

Reservations should be made by February 10, 2007 at the very latest (Download form from www.ctlag-congress.ch). After this date accommodation will not be available in the vicinity of the congress venue. To guarantee your reservation we kindly ask you to indicate your credit card and number on the registration form.

Posters

Posters will be exhibited in the poster area from Thursday to Friday.

Size of posters: 160 cm × 120 cm (height × width).

Industry Exhibition

The exhibition is located in the main congress area at the Congress Center Basel, and will be open from Thursday, 08.00 to Friday, 16.00 h.

Public Transport

Basel Central Station (SBB) to Congress Venue: tram (streetcar) No. 1 or 2 in direction to «Badischer Bahnhof» until tram stop «Exhibition Square» («Messeplatz»).

Parking

Parking: Messe Basel

Parking tickets can be bought at the registration desk.



Sponsors

The Scientific and Organizing Committees wish to acknowledge the financial support of the following companies (up-date until 17.10.2006):

Platin Sponsor

HERMAL
UCB Pharma AG

Gold Sponsors

Essex Chemie AG
Galderma SA
Mepha Pharma AG

Silver Sponsors

Abbott AG
Allergomed AG
Merck Sharp & Dohme
Spirig Pharma AG

In addition supported by

Becton Dickinson AG
Pharma Consulting
Stiftung für Wissenschaftliche Forschung

Antimykotika, Akne



Die mit dem Regenbogen

mepha





Gezielte Kraft gegen Akne

Tetralysal® 300 mg; **Zusammensetzung:** Wirkstoff: Lymecyclin 408 mg entsprechend 300 mg Tetracyclinbase. **Indikationen:** Acne vulgaris. **Dosierung/Anwendung:** 1 Kapsel einmal täglich, unabhängig vom Essen. **Therapiedauer:** Die klinische Besserung wird innerhalb von 4–8 Wochen sichtbar und setzt sich während der weiteren Behandlung fort, die 12 Wochen dauern kann. **Kontraindikationen:** Überempfindlichkeit gegenüber Tetracyclinen, schwere Nierenfunktionsstörungen, Kinder unter 8 Jahren, während einer Behandlung mit oralen Retinoiden, Schwangerschaft und Stillzeit. **Vorsichtsmassnahmen:** bei Patienten mit Leberfunktionsstörungen kann eine Überdosierung zu Hepatotoxizität führen, direkte Sonnen- und UV-Bestrahlung vermeiden. **Interaktionen:** orale Retinoide, orale Antikoagulantien vom Coumarin-Typ, Aluminium-, Calcium- oder Magnesium-haltige Antazida, Eisenhaltige Präparate und Wismut-Salze. **Unerwünschte Wirkungen:** gastrointestinale Störungen wie Durchfall, Übelkeit und Erbrechen; Störungen des Nervensystems wie Kopfschmerzen, Sehstörungen, Schwindel; Störungen des Immunsystems wie Urticaria, Überempfindlichkeitsreaktionen; Leberfunktionsstörungen; Störungen des Blut- und Lymphsystems wie Thrombozytopenie, Neutropenie, Leukopenie; Funktionsstörungen der Haut wie Ausschläge, Dermatitis, Photosensibilisierung. **Handelsform:** Packungen mit Blister à 28 Kapseln. Verkaufskategorie: A. Weitere Informationen entnehmen Sie bitte dem Arzneimittel-Kompendium der Schweiz. **Vertrieb/Distribution:** GALDERMA S.A., Postfach 492, CH-6330 Cham. *kassenzulässig

Tetralysal®
lymecyclinum

GALDERMA
SUISSE



Gibt Vertrauen bei Akne